Biological response modifiers (BRM), chemotherapy, and activated cytotoxic leukocyte subsets: strategies for rational design of apheresis-based cancer immunotherapies.
Stevenson
H C
HC
National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.
Klein
H G
HG
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001781:Blood Component Removal; D002985:Clinical Protocols; D003131:Combined Modality Therapy; D003602:Cytotoxicity, Immunologic; D006801:Humans; D007116:Immunization, Passive; D007155:Immunologic Factors / Q000627:therapeutic use; D007167:Immunotherapy / Q000379:methods*; D007962:Leukocytes / Q000276:immunology; D009369:Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*
D000970:Antineoplastic Agents; D007155:Immunologic Factors